HK1200469A1 - Phosphospecific antibodies recognising tau tau - Google Patents
Phosphospecific antibodies recognising tau tauInfo
- Publication number
- HK1200469A1 HK1200469A1 HK15100957.4A HK15100957A HK1200469A1 HK 1200469 A1 HK1200469 A1 HK 1200469A1 HK 15100957 A HK15100957 A HK 15100957A HK 1200469 A1 HK1200469 A1 HK 1200469A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- tau
- antibodies recognising
- phosphospecific antibodies
- phosphospecific
- recognising
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2440/00—Post-translational modifications [PTMs] in chemical analysis of biological material
- G01N2440/14—Post-translational modifications [PTMs] in chemical analysis of biological material phosphorylation
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Neurology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Food Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biophysics (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/EP2011/067604 WO2012045882A2 (en) | 2010-10-07 | 2011-10-07 | Pharmaceutical composition |
EP12163319 | 2012-04-05 | ||
PCT/EP2012/069783 WO2013050567A1 (en) | 2011-10-07 | 2012-10-05 | Phosphospecific antibodies recognising tau |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1200469A1 true HK1200469A1 (en) | 2015-08-07 |
Family
ID=48043196
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK15100957.4A HK1200469A1 (en) | 2011-10-07 | 2015-01-28 | Phosphospecific antibodies recognising tau tau |
Country Status (13)
Country | Link |
---|---|
US (2) | US9540434B2 (es) |
EP (2) | EP3135689B1 (es) |
JP (1) | JP6358953B2 (es) |
KR (1) | KR101981351B1 (es) |
CN (2) | CN108034005B (es) |
AR (1) | AR092779A1 (es) |
BR (2) | BR122021017560B1 (es) |
CA (1) | CA2850686C (es) |
ES (1) | ES2600915T3 (es) |
HK (1) | HK1200469A1 (es) |
MX (1) | MX354662B (es) |
RU (1) | RU2639537C2 (es) |
WO (1) | WO2013050567A1 (es) |
Families Citing this family (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR092779A1 (es) | 2011-10-07 | 2015-05-06 | Ac Immune Sa | Composicon farmaceutica que comprende anticuerpos que se unen a conformeros de proteinas tau |
CA2869438C (en) | 2012-04-05 | 2021-08-17 | Ac Immune S.A. | Humanized tau antibody |
RU2668159C2 (ru) | 2012-07-03 | 2018-09-26 | Вашингтон Юниверсити | Антитела против тау |
BR112015003326A2 (pt) | 2012-08-16 | 2017-07-04 | Ipierian Inc | métodos de tratamento de uma tauopatia |
US8980270B2 (en) | 2013-01-18 | 2015-03-17 | Ipierian, Inc. | Methods of treating a tauopathy |
JP6674888B2 (ja) | 2013-03-13 | 2020-04-01 | プロセナ バイオサイエンシーズ リミテッド | タウ免疫療法 |
JP6568514B2 (ja) | 2013-03-15 | 2019-08-28 | エーシー イミューン エス.エー. | 抗タウ抗体及び使用方法 |
GB201319656D0 (en) * | 2013-11-07 | 2013-12-25 | Univ Leuven Kath | A yeast model for synergistic toxicity |
US10400018B2 (en) | 2014-02-14 | 2019-09-03 | Ipierian, Inc. | Tau peptides, anti-tau antibodies, and methods of use thereof |
US10400034B2 (en) * | 2014-06-26 | 2019-09-03 | Janssen Vaccines & Prevention, B.V. | Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau |
ZA201608812B (en) * | 2014-06-26 | 2019-08-28 | Janssen Vaccines & Prevention Bv | Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau |
TWI664190B (zh) | 2014-06-27 | 2019-07-01 | 美商C2N醫療診斷有限責任公司 | 人類化抗-tau抗體 |
WO2016007414A1 (en) * | 2014-07-08 | 2016-01-14 | New York University | Tau imaging ligands and their uses in the diagnosis and treatment of tauopathy |
DE102014013571A1 (de) * | 2014-09-18 | 2016-03-24 | Aj Roboscreen Gmbh | Monoklonaler Antikörper gegen humanes TAU-Protein |
EP3200832B1 (en) | 2014-09-30 | 2020-07-29 | Washington University | Tau kinetic measurements |
JO3576B1 (ar) | 2015-02-26 | 2020-07-05 | Lilly Co Eli | أجسام مضادة لـ tau واستخداماتها |
JP6793134B2 (ja) | 2015-06-05 | 2020-12-02 | ジェネンテック, インコーポレイテッド | 抗tau抗体及び使用方法 |
JO3711B1 (ar) * | 2015-07-13 | 2021-01-31 | H Lundbeck As | أجسام مضادة محددة لبروتين تاو وطرق استعمالها |
US10358503B2 (en) * | 2015-08-13 | 2019-07-23 | New York University | Antibody-based molecules selective for the {P}Ser404 epitope of Tau and their uses in the diagnosis and treatment of tauopathy |
KR102533675B1 (ko) | 2016-05-02 | 2023-05-22 | 프로테나 바이오사이언시즈 리미티드 | 타우 인식 항체 |
FI3452507T3 (fi) | 2016-05-02 | 2022-12-15 | Tau-immuunihoito | |
EA201892417A1 (ru) | 2016-05-02 | 2019-05-31 | Протена Биосайенсис Лимитед | Антитела, распознающие тау |
GEP20217222B (en) | 2016-07-12 | 2021-02-10 | Lundbeck A/S H | Antibodies specific for hyperphosphorylated tau and methods of use thereof |
US10988529B2 (en) | 2016-08-09 | 2021-04-27 | Eli Lilly And Company | Combination therapy |
AR110321A1 (es) * | 2016-12-07 | 2019-03-20 | Genentech Inc | Anticuerpos antitau y métodos de uso |
JP2020511937A (ja) | 2016-12-07 | 2020-04-23 | ジェネンテック, インコーポレイテッド | 抗tau抗体及び使用方法 |
MA47205A (fr) * | 2017-01-04 | 2019-11-13 | H Lundbeck As | Anticorps spécifiques de la protéine tau hyperphosphorylée pour traiter des maladies oculaires |
WO2018152359A1 (en) | 2017-02-17 | 2018-08-23 | Denali Therapeutics Inc. | Anti-tau antibodies and methods of use thereof |
EA039569B1 (ru) * | 2017-03-14 | 2022-02-11 | Х. Лундбекк А/С | Антитела, специфичные к гиперфосфорилированному тау-белку, и способы их применения |
CN110881274A (zh) | 2017-05-02 | 2020-03-13 | 普罗塞纳生物科学有限公司 | 识别tau的抗体 |
TW201946654A (zh) * | 2018-03-05 | 2019-12-16 | 比利時商健生藥品公司 | 抗PHF-Tau抗體及其用途 |
CA3090356A1 (en) * | 2018-03-11 | 2019-09-19 | Koorosh Shahpasand | Conformation-independent antibodies against neurotoxic tau proteins |
US11085935B2 (en) | 2018-05-03 | 2021-08-10 | Washington University | Methods of treating based on site-specific tau phosphorylation |
MX2020011458A (es) * | 2018-05-03 | 2020-12-07 | Washington University St Louis | Metodos de diagnostico y tratamiento basados en fosforilacion de tau especifica del sitio. |
WO2020028141A1 (en) | 2018-07-31 | 2020-02-06 | Eli Lilly And Company | Combination therapy |
US12016885B2 (en) | 2018-11-06 | 2024-06-25 | Alsatech, Inc. | Method of solubilizing TDP-43 protein aggregates in amyotrophic lateral sclerosis using a microvascular endothelial cell expressing an anti-TDP-43 Fab |
BR112021016947A2 (pt) | 2019-03-03 | 2021-11-03 | Prothena Biosciences Ltd | Anticorpos que reconhecem tau |
EP3948295A1 (en) * | 2019-03-28 | 2022-02-09 | H. Lundbeck A/S | Use of a ps396 assay to diagnose tauophaties |
CA3148740A1 (en) * | 2019-08-06 | 2021-02-11 | Aprinoia Therapeutics Limited | Antibodies that bind to pathological tau species and uses thereof |
CN111690061B (zh) * | 2020-06-28 | 2022-08-23 | 中国人民解放军东部战区疾病预防控制中心 | 人源化抗鼠疫耶尔森菌抗原f1的抗体及应用 |
EP4252243A2 (en) | 2020-11-30 | 2023-10-04 | Enigma Biointelligence, Inc. | Non-invasive assessment of alzheimer's disease |
MX2023007181A (es) * | 2020-12-16 | 2023-08-30 | Voyager Therapeutics Inc | Compuestos de union a tau. |
CN112694532B (zh) * | 2021-01-12 | 2023-04-18 | 倍而达药业(苏州)有限公司 | 抗Siglec-15的抗体或其抗原结合片段及应用 |
CN113533746B (zh) * | 2021-07-22 | 2022-05-10 | 深圳市天大生物医疗器械有限公司 | 一种P-Tau蛋白化学发光检测试剂盒及其制备方法 |
CN114002435A (zh) * | 2021-10-13 | 2022-02-01 | 华中科技大学 | 三种用于检测人磷酸化Tau蛋白的试剂盒及其制备方法 |
WO2023092004A1 (en) | 2021-11-17 | 2023-05-25 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of tau-related disorders |
CN117003863A (zh) * | 2022-04-28 | 2023-11-07 | 厦门大学 | 针对p-tau 217的抗体及其用途 |
CN114778856B (zh) * | 2022-05-30 | 2023-03-17 | 苏州宇测生物科技有限公司 | 磷酸化tau蛋白检测试剂盒 |
CN117866087B (zh) * | 2024-03-11 | 2024-05-17 | 江西赛基生物技术有限公司 | 一种抗pTau181单克隆抗体及其应用 |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5004697A (en) | 1987-08-17 | 1991-04-02 | Univ. Of Ca | Cationized antibodies for delivery through the blood-brain barrier |
US5112596A (en) | 1990-04-23 | 1992-05-12 | Alkermes, Inc. | Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability |
US5268164A (en) | 1990-04-23 | 1993-12-07 | Alkermes, Inc. | Increasing blood-brain barrier permeability with permeabilizer peptides |
ATE206755T1 (de) * | 1991-08-09 | 2001-10-15 | Massachusetts Inst Technology | Verwendungen einer proteinkinase von ton und neurofilament pk40 |
EP0911390B1 (en) | 1991-12-06 | 2009-08-05 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Protein kinases as tools for the diagnosis and treatment of Alzheimer's disease |
CA2141216A1 (en) | 1992-07-27 | 1994-02-03 | Michael J. Micklus | Targeting of liposomes to the blood-brain barrier |
JPH10507643A (ja) | 1994-10-21 | 1998-07-28 | イノジェネティックス・ナムローゼ・フェンノートシャップ | C型肝炎ウイルス遺伝子型の新規配列、ならびにそれらの予防薬、治療薬および診断薬としての使用 |
US5756662A (en) | 1995-03-14 | 1998-05-26 | Corixa Corporation | Compounds and methods for the detection of T. cruzi infection |
US20020086009A1 (en) | 1996-03-13 | 2002-07-04 | Koichi Ishiguro | Anti-phosphorylated tau protein antibodies and methods for detecting alzheimer`s disease with the use of the same |
WO1998022120A1 (en) * | 1996-11-19 | 1998-05-28 | The Wistar Institute Of Anatomy & Biology | Diagnostic and therapeutic reagents for alzheimer's disease |
MXPA03000316A (es) | 2000-07-11 | 2004-04-05 | Molecular Geriatrics Corp | Reactivos y metodos para la identificacion de agentes de enlace. |
US6514221B2 (en) | 2000-07-27 | 2003-02-04 | Brigham And Women's Hospital, Inc. | Blood-brain barrier opening |
AU2001286930A1 (en) | 2000-08-30 | 2002-03-13 | The Board Of Trustees Of The Leland Stanford Junior University | Glucocorticoid blocking agents for increasing blood-brain barrier permeability |
US7034036B2 (en) | 2000-10-30 | 2006-04-25 | Pain Therapeutics, Inc. | Inhibitors of ABC drug transporters at the blood-brain barrier |
US20030083299A1 (en) | 2000-11-04 | 2003-05-01 | Ferguson Ian A. | Non-invasive delivery of polypeptides through the blood-brain barrier |
AT500379B8 (de) * | 2001-02-02 | 2009-08-15 | Axon Neuroscience | Tau-proteine |
DE10121982B4 (de) | 2001-05-05 | 2008-01-24 | Lts Lohmann Therapie-Systeme Ag | Nanopartikel aus Protein mit gekoppeltem Apolipoprotein E zur Überwindung der Blut-Hirn-Schranke und Verfahren zu ihrer Herstellung |
DE60234057D1 (de) | 2001-07-25 | 2009-11-26 | Raptor Pharmaceutical Inc | Zusammensetzungen und verfahren zur modulation des transports durch die blut-hirn-schranke |
US20030162695A1 (en) | 2002-02-27 | 2003-08-28 | Schatzberg Alan F. | Glucocorticoid blocking agents for increasing blood-brain barrier permeability |
KR101111477B1 (ko) | 2002-12-03 | 2012-02-23 | 블랜체트 록펠러 뉴로사이언시즈 인스티튜트 | 치료제와 연결된 콜레스테롤을 포함하는 접합체 |
JP2006512417A (ja) | 2002-12-24 | 2006-04-13 | ニューロケム (インターナショナル) リミテッド | β−アミロイド関連疾患の治療のための治療用製剤 |
US20050089473A1 (en) | 2003-09-10 | 2005-04-28 | Cedars-Sinai Medical Center | Potassium channel mediated delivery of agents through the blood-brain barrier |
CN101325972B (zh) * | 2005-12-12 | 2020-06-16 | Ac免疫有限公司 | 具有治疗性质的Aβ1-42特异性单克隆抗体 |
US8012936B2 (en) | 2006-03-29 | 2011-09-06 | New York University | Tau fragments for immunotherapy |
US8428434B2 (en) * | 2006-10-23 | 2013-04-23 | Pioneer Corporation | Video reproducing apparatus, video display system and record medium |
WO2008140639A2 (en) * | 2007-02-08 | 2008-11-20 | Oligomerix, Inc. | Biomarkers and assays for alzheimer's disease |
CA2692039C (en) | 2007-06-13 | 2019-07-02 | Research Development Foundation | Methods for treatment and prevention of tauopathies and amyloid beta amyloidosis by modulating crf receptor signaling |
US9403902B2 (en) * | 2007-10-05 | 2016-08-02 | Ac Immune S.A. | Methods of treating ocular disease associated with amyloid-beta-related pathology using an anti-amyloid-beta antibody |
KR20100115340A (ko) * | 2007-10-19 | 2010-10-27 | 이무나스 파마 가부시키가이샤 | Aβ 올리고머에 특이적으로 결합하는 항체 및 그의 이용 |
SI2408807T1 (sl) | 2009-03-18 | 2021-11-30 | Ac Immune Sa | Postopek za terapevtsko uporabo |
UA107571C2 (xx) * | 2009-04-03 | 2015-01-26 | Фармацевтична композиція | |
CN106390107B (zh) * | 2009-06-10 | 2019-12-31 | 纽约大学 | 病理tau蛋白的免疫靶向 |
KR20130127547A (ko) | 2009-07-30 | 2013-11-22 | 화이자 백신스 엘엘씨 | 항원성 타우 펩타이드 및 이의 용도 |
CN102070718A (zh) | 2010-03-23 | 2011-05-25 | 中国疾病预防控制中心病毒病预防控制所 | 人tau蛋白外显子2、外显子3、外显子10多克隆抗体 |
MY164376A (en) | 2010-10-07 | 2017-12-15 | Univ Leuven Kath | Phosphospecific antibodies recognizing tau |
AR092779A1 (es) | 2011-10-07 | 2015-05-06 | Ac Immune Sa | Composicon farmaceutica que comprende anticuerpos que se unen a conformeros de proteinas tau |
CA2869438C (en) * | 2012-04-05 | 2021-08-17 | Ac Immune S.A. | Humanized tau antibody |
WO2013166302A1 (en) | 2012-05-02 | 2013-11-07 | Ibis Biosciences, Inc. | Nucleic acid sequencing systems and methods |
-
2012
- 2012-10-05 AR ARP120103738A patent/AR092779A1/es unknown
- 2012-10-05 MX MX2014004026A patent/MX354662B/es active IP Right Grant
- 2012-10-05 ES ES12769656.5T patent/ES2600915T3/es active Active
- 2012-10-05 EP EP16180969.4A patent/EP3135689B1/en active Active
- 2012-10-05 US US14/348,918 patent/US9540434B2/en active Active
- 2012-10-05 CA CA2850686A patent/CA2850686C/en active Active
- 2012-10-05 KR KR1020147012061A patent/KR101981351B1/ko active IP Right Grant
- 2012-10-05 BR BR122021017560-8A patent/BR122021017560B1/pt active IP Right Grant
- 2012-10-05 EP EP12769656.5A patent/EP2764022B9/en active Active
- 2012-10-05 RU RU2014118456A patent/RU2639537C2/ru active
- 2012-10-05 CN CN201711419092.7A patent/CN108034005B/zh active Active
- 2012-10-05 CN CN201280060349.3A patent/CN104080806B/zh active Active
- 2012-10-05 BR BR112014008202-2A patent/BR112014008202B1/pt active IP Right Grant
- 2012-10-05 WO PCT/EP2012/069783 patent/WO2013050567A1/en active Application Filing
- 2012-10-05 JP JP2014533928A patent/JP6358953B2/ja active Active
-
2015
- 2015-01-28 HK HK15100957.4A patent/HK1200469A1/xx unknown
-
2016
- 2016-10-28 US US15/337,964 patent/US10066010B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
US9540434B2 (en) | 2017-01-10 |
KR101981351B1 (ko) | 2019-09-02 |
RU2639537C2 (ru) | 2017-12-21 |
MX2014004026A (es) | 2014-08-27 |
CN108034005A (zh) | 2018-05-15 |
BR112014008202A2 (es) | 2017-08-15 |
RU2014118456A (ru) | 2015-11-20 |
BR112014008202B1 (pt) | 2022-01-04 |
US10066010B2 (en) | 2018-09-04 |
CN104080806B (zh) | 2018-01-19 |
EP2764022B1 (en) | 2016-08-17 |
CA2850686C (en) | 2020-09-08 |
WO2013050567A1 (en) | 2013-04-11 |
EP2764022A1 (en) | 2014-08-13 |
EP3135689A1 (en) | 2017-03-01 |
ES2600915T3 (es) | 2017-02-13 |
US20170137502A1 (en) | 2017-05-18 |
CA2850686A1 (en) | 2013-04-11 |
AR092779A1 (es) | 2015-05-06 |
EP2764022B9 (en) | 2017-02-22 |
MX354662B (es) | 2018-03-14 |
EP3135689B1 (en) | 2018-12-19 |
CN108034005B (zh) | 2021-06-25 |
BR122021017560B1 (pt) | 2023-03-07 |
US20140294731A1 (en) | 2014-10-02 |
CN104080806A (zh) | 2014-10-01 |
KR20140070658A (ko) | 2014-06-10 |
JP6358953B2 (ja) | 2018-07-18 |
JP2014531216A (ja) | 2014-11-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1200469A1 (en) | Phosphospecific antibodies recognising tau tau | |
IL225568A0 (en) | Phospho-specific antibodies to detect tau | |
IL251697A0 (en) | Antibodies against 3erbb and their uses | |
IL264558A (en) | Anti–il–23p19 antibodies | |
HK1209137A1 (en) | Humanized tau antibody tau | |
ZA201407509B (en) | Anti-fcrn antibodies | |
HK1204571A1 (en) | Protease-regulated antibodies | |
HK1210192A1 (en) | Anti-siglec-15 antibodies siglec-15 | |
GB201103955D0 (en) | Antibodies | |
EP2870176A4 (en) | ANTIBODIES DIRECTED AGAINST TAU | |
GB201112056D0 (en) | Antibodies | |
EP2722343A4 (en) | ANTI-ERBB3 ANTIBODIES | |
HK1210186A1 (en) | Anti-h7cr antibodies h7cr | |
PL2935330T3 (pl) | Przeciwciała przeciw notch3 | |
EP2714074A4 (en) | ANTIBODIES AGAINST EMR1 | |
IL235188A0 (en) | Antibodies against c-pdgf |